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SUMMARY 
Crohn's disease (CD) is associated with low bone mass due to chronic inflammation and other factors. Receptor 
activator of NF-κB ligand (RANKL), its receptor RANK and its decoy receptor osteoprotegerin (OPG) are 
potentially involved in this process as they regulate osteoclastogenesis and are influenced by pro-inflammatory 
cytokines. The aim of this study was to determine the levels of soluble RANKL (sRANKL), RANK and OPG 
expression both in the serum and in the colon of CD patients. Levels of sRANKL and OPG were assessed in the 
serum and the supernatants of cultured colonic biopsies in patients with CD and controls by ELISA. RANK 
expression was explored by immunostaining and immunofluorescence of fixed colonic samples. OPG and 
sRANKL levels were higher in the serum of CD patients as compared to age- and sex-matched controls. Levels 
of sRANKL and OPG were significantly enhanced in cultured colonic biopsies from CD, and OPG levels 
correlated with histological inflammation, and pro- and anti-inflammatory cytokine levels. No significant 
correlation was found for sRANKL. RANK+ cells were increased in the colon of CD, particularly in inflamed 
areas. These cells were positive for CD68 or S100 protein. We conclude that serum and local levels of sRANKL 
and OPG are increased in CD. Moreover, RANK is expressed in the colonic mucosa by subpopulations of 
activated macrophages or dendritic cells at higher levels in CD compared to normal colon. 
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INTRODUCTION 
Crohn's disease (CD) is a chronic inflammatory disorder of the gastrointestinal tract. The aetiology of the disease 
is not fully understood but an abnormal immuno-inflammatory reaction takes place in the bowel wall [1].This 
abnormal reaction is characterized by an increased number and an aberrant activation of T lympocytes and 
monocytes-macrophages. A predominant production of Thl cytokines and an excessive activation of NF-κB are 
observed consequently [2,3]. While CD is mainly an inflammatory bowel disease, it is frequently associated with 
extra-intestinal manifestations and in particular, with an increased risk of osteopenia, osteoporosis, and fractures 
[4-9]. Mechanisms responsible for bone loss in CD are various including calcium and vitamin D deficiency, 
steroid treatment, but also chronic inflammation [10] as a result of longstanding elevation of circulating pro-
inflammatory cytokines. 
The production of the Receptor Activator of NF-κB ligand (RANKL), notably by T lymphocytes or by 
osteoblasts has recently been identified as a potential mechanism underlying bone loss in systemic inflammatory 
diseases [11]. After binding to its receptor RANK, RANKL increases osteoclast development, osteoclast activity 
and survival [12]. Moreover, RANKL expression in osteoblasts is stimulated by pro-inflammatory cytokines 
[12]. In this case, RANKL may be produced in the bone microenvironment in response to high levels of 
circulating proinflammatory cytokines including tumour necrosis factor (TNF) and interleukin (IL)-1 [12]. 
Alternatively, RANKL could also be produced in the gut and act in an endocrine manner on bone metabolism. In 
physiological conditions, RANKL is not highly expressed in the intestine but RANKL expression in both T-cells 
and osteoblastic cells is known to be tightly regulated [13,14]. 
Cell response to RANKL depends on the level of expression of its receptor RANK but also on the presence of its 
decoy receptor OPG. By binding to RANKL, OPG prevents RANK activation and signalling as observed in bone 
remodeling where OPG acts as a potent inhibitor of osteoclastogenesis [15]. OPG is highly expressed in bone 
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marrow stromal cells but OPG transcripts are detected in the gastrointestinal tract of mouse embryo [14,15]. 
OPG synthesis is induced in B lymphocytes, dendritic cells (DC) and follicular DC, notably through CD40 - 
CD40 ligand interaction [16]. However, the exact role played by OPG in the immune system is presently not 
well understood. 
If RANKL and OPG were produced in significant amount in the colon, it would be critical to know the level of 
RANK expression in the colon in the light of the prominent role played by RANKL-RANK interaction on T 
lymphocytes and DC [17,18]. While RANK mRNA is detected in many tissues in mice including the small and 
large intestines, RANK protein expression is mainly detectable on the surface of mature DC [19]. RANKL-
RANK interaction results in an increase in DC survival and DC production of cytokines [18,19]. 
The first aim of our study was to determine the level of sRANKL and OPG proteins in the serum of CD patients. 
As serum levels were found to be increased in CD, we next looked at the local production of sRANKL and OPG 
in the colonic mucosa and we also tested the possibility of a local function for sRANKL and OPG by studying 
RANK colonic expression in CD patients. 
 
METHODS 
Serum levels of sRANKL and OPG in CD  
Twenty-five patients with CD, prospectively seen at our outpatient clinic, were recruited for serum level 
measures. Diagnosis of CD was made on the basis of clinical, radiological and histological data, according to 
standard criteria [20]. Clinical characteristics of the patients were recorded during the medical visit and are 
shown in Table 1. Crohn's Disease Activity Index (CDAI) [21] were retrospectively calculated, based on the 
symptoms of the last week. Fifteen had active disease, defined by a CDAI >150 and 10 had inactive disease. 
Median CDAI was 283 (range 79-609) and median CRP was 22 mg/l (range 3-148 mg/l). These patients were 
compared to 18 age- and sex-matched controls, who were laboratory workers. Serum samples were collected and 
stored at -20°C before OPG and sRANKL measurements. Levels of OPG were measured using a sandwich 
enzyme-linked immunosorbent assay procedure (R & D Systems, Minneapolis, MN, USA). Levels of sRANKL 
were measured with an improved sensitivity ELISA according to the manufacturer's recommendations 
(Biomedica Gesellschaft mbH., Wien, Austria). Results were expressed in pg/ ml for OPG and for sRANKL. 
Sensitivity of the test was 5 pg/ml and 1.6 pg/ml for OPG and RANKL, respectively. 
Production of  sRANKL, OPG, and correlation to pro- and anti-inflammatory cytokines by colonic mucosa 
Intestinal biopsies. Colonic biopsies were obtained in macroscopically and microscopically unaffected or 
affected areas from 23 consecutive CD patients undergoing colonoscopy for medical reason. Characteristics of 
the patients are given in Table 1. We were able to collect biopsies in both inflamed (I) and uninflamed (UN) 
areas for 6 of these patients (paired biopsies), we could collect biopsies only in uninflamed area in 8 patients and 
only in inflamed area in 9 patients. The control group included 7 patients without inflammatory bowel disease 
who underwent endoscopy for irritable bowel syndrome or polyp/cancer screening. All controls were free of 
colonic lesion. The protocol was approved by the Ethic Committee of Liège University Hospital. 
Tissue culture. After collection, biopsy specimens were transferred to the laboratory and handled within a 
maximal lag of 3 h after biopsy. Tissues were gently washed three times in CMF-Hank's medium (Gibco, 
Invitrogen, Merelbeke, Belgium) supplemented with antibiotics, blotted carefully, weighted and individually 
placed in 24-well tissue culture plates in triplicates. Intestinal tissues were cultured in RPMI 1640 (Gibco) 
supplemented with 10% heat-inactivated fetal calf serum (FCS, Gibco), 2 mM L-glutamine (Gibco), penicillin 
(100 U/ml), and streptomycin (100 µg/ml) at 37°C in a humidified 95% air/5% CO2 as previously described 
[22]. After 18 h, culture media were collected, centrifuged and stored at -80°C until required for immunoassays. 
Lactate dehydrogenase levels were measured to control for the absence of necrosis at the end of the culture 
period and histological analyses were performed in parallel to demonstrate structural integrity [23]. 
Immunoassays. Levels of OPG and sRANKL produced in the culture medium of CD patients and controls were 
analysed using a sandwich enzyme-linked immunosorbent assay procedure as described above. Results were 
corrected for the weight of the biopsy and expressed as pg/ml of OPG or sRANKL per mg of tissue. TNF-α, IL-1 
β, IL-6, IL-10 and MMP-3 production were measured with specific immunoassays, according to manufacturer's 
instructions (EASIA, from Biosources Europe, Fleurus, Belgium). Results were corrected for the weight of the 
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biopsy and expressed as pg/ml per mg of tissue. The median weight of the biopsies was 13.7 mg (6.3 mg-27.2 
mg). Sensitivity of the ELISA were 5 pg/ml, 1.6 pg/ml, 3 pg/ml, 2 pg/ml, 2 pg/ml, 1 pg/ml and 100 pg/ml, for 
OPG, sRANKL, TNF-α, IL-1β IL-6, IL-10 and MMP-3, respectively. For OPG, sRANKL, the cytokines and 
MMP-3, the final result corresponds to the mean of 3 individual tissue cultures obtained from the same patient. 
The mean coefficient of variation between the 3 individual biopsies was 27.2% ± 13.1 for OPG, 31.4% ± 15.4 
for sRANKL, 33.6% ± 13.5 for TNF-α, 23.4% ± 12.7% for IL-1β, 42.1% ± 13.1 for IL-6, 34.5% ± 14.3 for IL-
10, and 34.2% ± 11.7 for MMP-3. 
 
Table 1. Characteristics of the Crohn's disease (CD) patients (n = 57) 
 CD patients included  
in the serum level 
measures  
(n = 25) 
CD patients included  
in the colonic biopsy 
supernatant measures  
(n = 23) 
CD patients included  
in the immunohisto-
chemistry study  
(n = 9) 
Age (years)† 35 (20-64) 37 (18-51) 29 (22-57) 
Disease duration (months)† 108 (10-289) 94 (7-317) 75 (5-405) 
Gender (F/M) 15/10 16/7 6/3 
Disease location (Vienna classification) 
L1 1 3 0 
L2 11 12 4 
L3 12 8 5 
L4 1 0 0 
Treatment 
Glucocorticoids 19 10 5 
Mesalamine 15 11 4 
Immunosupp. 15 7 3 
Antibiotics 8 5 1 
†median (range) 
 
Immunostaining and immunofluorescence for RANK expression in the colon 
We used surgically resected colonic specimens from 5 controls and 9 CD patients (9 and 5 tissue samples, in 
inflamed (I) and uninflamed (UN) areas, respectively) for immunostaining and immunofluorescence. The 5 
controls had underwent surgery for colorectal cancer and tissue samples were taken at distance from the cancer. 
The 9 CD patients had underwent surgery for either stricturing complication (n = 4), fistulizing complication (n 
= 4), or disease refractory to medical treatment (n = 1). Characteristics of the patients are shown in Table 1. 
Tissue samples had been fixed in formalin and embedded in paraffin according to routine procedures and were 
stored at the pathology department of Liège University Hospital. 
Briefly, five-micron sections of the biopsy specimens were deparaffinized and incubated with H2O2 (3% in 
methanol) for 10 min. Antigen retrieval was then performed by treating the slides for 5 min in boiling heat 
cooker in EDTA buffer (1 mM; pH 9.0). After washing in distilled water, sections were permeabilized using 
Tween (0.015%; pH 7.2) in PBS buffer and incubated at room temperature with an anti-RANK monoclonal 
antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA) for 30 min at a dilution of 1/500 for 
immunoperoxydase and for 60 min at a dilution of 1/250 for immunofluorescence. The slides were then washed 
and incubated at room temperature for 30 min with goat antirabbit immunoglobulins conjugated to peroxydase 
(Envision + ; DAKO A/S, Glostrup, Denmark) or for 60 min with swine antirabbit FITC-antibody (1/40; DAKO 
A/S). The first antibody (anti-RANK) was omitted as a negative control. Fluorescent positive cells were 
visualized by using a fluorescent microscope (Leica DMLB microscope, Heidelberg GmBH, Germany) equipped 
with a 40x objective whereas immunoperoxydase staining was evaluated by light microscopy after chromogenic 
revelation with diaminobenzidine (0.5 mg/ml). To compare RANK expression between CD and control tissues, 
the density of immunofluores-cent cells was precisely determined by selecting 5 fields in the most positive 
regions of each section and by counting the number of positive cells per field at 400x magnification. The mean 
value was then calculated and recorded for each section [24]. 
In order to identify RANK-expressing cells, serial sections were analysed by using the same immunostaining 
protocol with the following antibodies: CD3 polyclonal rabbit antibody (1/40; DAKO), CD1a monoclonal mouse 
antibody (1/10; NOVOCAS TRA, Newcastle, UK), CD20 monoclonal mouse antibody (1/2000; DAKO), CD68 
monoclonal mouse antibody (1/3500; DAKO), MAC3S7 monoclonal mouse antibody(1/1600; DAKO), S100 
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polyclonal rabbit antibody (1/2000; DAKO). 
A double RANK/S100 and RANK/CD68 immunostaining was also carried out. After RANK immunodetection 
performed as already described, sections were rinced in PBS Tween (0.015% pH 7,2), then incubated at room 
temperature with either S100 polyclonal rabbit antibody (1/2000) or with CD68 monoclonal mouse antibody 
(1/3500). The sections were then washed and incubated for 30 min at room temperature with anti mouse/anti-
rabbit antibody coupled to alkaline phosphatase (DAKO). After washing, the chromogenic revelation was 
performed with fast red (DAKO). 
Statistical analysis 
Levels of OPG and sRANKL in the serum and in the supernatants of cultured colonic biopsies were expressed as 
median (interquartile range) and were compared by the Mann-Whitney test. Levels of OPG and sRANKL in the 
supernatants of paired cultured biopsies were compared by the Wilcoxon test. Correlations between OPG or 
sRANKL levels in the serum and CDAI or CRP as well as between OPG and sRANKL in the culture 
supernatants and pro- or anti-inflammatory cytokines were studied by the Spearman test. The number of RANK+ 
labelled cells/field in the colon of controls, I and UN CD were expressed as median (range) and were compared 
by the Mann-Whitney test. For all these tests, the differences were considered as significant at P < 0.05. 
RESULTS 
Serum levels of sRANKL and OPG in CD  
OPG and sRANKL serum levels were significantly higher in CD patients than in controls (Figs 1 and 2). OPG 
and sRANKL serum levels were not significantly higher in clinically active (CDAI >150), than in clinically 
inactive CD (OPG: 1405 pg/ml (800-1695) and 1075 pg/ml (830-1655), respectively; sRANKL: 4.0 pg/ ml 
(range 1.4-8.86 pg/ml) and 5.0 pg/ml (range l.7-7.4 pg/ml) respectively). There was no significant correlation 
between CDAI and sRANKL or OPG serum concentrations. However, CRP levels in the serum correlated to 
those of OPG (r = 0.48; P =0.05) but not to those of RANKL. 
 
Fig. 1. Serum levels of OPG in Crohn's disease (CD) and controls. Levels of OPG in the serum of 25 patients 
with CD and 18 sex- and age- matched normal subjects (controls) measured by ELISA. Results are expressed in 
pg/ml. Horizontal bars correspond to the medians. CD and controls were compared with a Mann-Whitney test. 
Median levels and interquartile ranges were 540-5 pg/ml (range 479-634) and 1150 pg/ml (range 830-1690), in 




Fig. 2. Serum levels of sRANKL in Crohn's disease (CD) and controls. Levels of sRANKL in the serum of 25 
patients with CD and 18 sex- and age- matched normal subjects (controls) measured by ELISA. Results are 
expressed in pg/ml. Horizontal bars correspond to the medians. CD and controls were compared with a Mann-
Whitney test. Median levels and interquartile ranges were 2.71 pg/ml (1.6-4.14) and 5.0 pg/ml (3.26-7.4), in 
controls and CD, respectively (P =  0.033). 
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Production of sRANKL and OPG by colonic mucosa. Correlation with pro- and anti-inflammatory cytokines  
We first confirmed by RT-PCR that RANKL, RANK and OPG transcripts were present in human colonic 
biopsies (data not shown). We next studied protein levels of sRANKL and OPG by immunoassay. Levels of 
OPG in supernatants of cultured colonic biopsies were significantly higher in CD than in controls and were 
higher in I than UN areas (6.6 pg/mg ml (range 4.2-6.8 pg/ml), 9.0 pg/mg ml (range 8.6-12.5 pg/ml), and 23.7 
pg/mg ml (range 15.6-79.2 pg/ml), in controls, UN and I, respectively; P = 0.0016 between controls and UN; P 
< 0.0001 between UN and I areas of (CD) (Fig. 3). When comparing I and UN areas in paired biopsies, OPG 
levels were also significantly higher in I areas of CD patients (P = 003). Levels of sRANKL were also higher in 
supernatants of UN CD biopsies than in controls (1.2 pg/mg.ml (0.89-1.49) and 0.46 pg/mg.ml (0.34-0.57), 
respectively; P = 0.0066), but there was no further significant increase in I CD (1.03 pg/mg.ml (0.85-3.18); P = 
0.58) (Fig. 4). When comparing paired biopsies in I and UN areas of CD patients, there was no significant 
difference either. Correlations between OPG, sRANKL and pro- (TNF, IL-1, IL-6) or anti-inflammatory (IL-10) 
cytokines in CD are shown in Table 2. OPG was significantly correlated to all pro- and anti-inflammatory 
cytokines tested, while sRANKL did not significantly correlate to pro- neither to anti-inflammatory cytokines. 
MMP-3 was chosen as a marker of tissue destruction [25]. OPG, but not RANKL, was significantly correlated to 
this protease [Table 2]. 
 
 
Fig. 3. Production of OPG by colonic mucosa. Levels of OPG in supernatants of cultured colonic biopsies 
obtained from 23 CD patients in mac-roscopically and microscopically uninflamed (UN, n = 14) or inflamed (I, 
n = 15) areas and 7 patients free of intestinal disease (Controls) during colonoscopy (UN CD versus controls: P 




Fig. 4. Production of sRANKL by colonic mucosa. Levels of sRANKL in supernatants of cultured colonic 
biopsies obtained from 23 CD patients in macroscopically and microscopically uninflamed (UN, n = 14) or 
inflamed (I, n = 15) areas and 7 patients free of intestinal disease (Controls) during colonoscopy (UN CD 
versus. controls: P = 0.0066; UN CD versus. I CD: P= 0.58). After collection, biopsy specimens were washed 
before weighting and cultured in triplicate as indicated in the methods. OPG and sRANKL levels in the 
supernatant were measured by ELISA. Results are expressed in pg/ml per mg of tissue (pg/mlmg) and 




Table 2. Correlation between cytokines, MMP-3 and OPG or sRANKL in the supernatant of cultured colonic 
biopsies (Spearman test). 
 TNFα IL1β IL-6 IL-10 MMP3 
P = 0.016; P = 0.002; P < 0.0001; P = 0.002; P < 0.0001; OPG 
r = 0.53 r = 0.65 r = 0.80 r = 0.65 r = 0.79 
sRANKL P = 0.87 P =0.71 P = 0.84 P = 0.95 P = 0.59 
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RANK expression in the colon by immunofluorescence and immunostaining 
Immunoperoxydase demonstrated the presence of RANK-positive cells in the mucosal layer of the intestine and, 
at a lesser extent, in the submucosa. No or very little RANK immunoreactivity was detected in the muscularis 
propria and in the subserosa. This was mainly seen in CD and less visible in controls where only isolated 
lymphoid follicles showed a focal staining in the germinal centres. Positive cells were essentially large 
mononuclear cells (Fig. 5a,b). After immunofluorescence, the different densities of positive cells between 
controls and CD became more evident (Fig.5c-e). The  density of RANK+ cells was significantly increased in 
inflamed areas of CD patients as compared to controls (16.8 (2.2-41.6) versus. 4.2 (0-10), respectively; P = 
0.048), but there was no significant difference with uninflamed area, either in positive cell density (12.5 (0.2-
24.6)) or in staining distribution. 
As RANK+ cells exhibited morphological features of inflammatory mononuclear cells, serial sections were used 
to compare the immunostaining patterns of RANK and of markers of lymphocytes (CD3, CD20), macrophages 
(MAC387, CD68) and dendritic cells (CD1a, S100). There was a close correlation between RANK and CD68 or 
S100 immunostaining patterns. A double RANK/S100 and RANK/CD68 immunostaining was then carried out 
to further identify the nature of RANK+ cells. As shown in Fig. 5f,g, many cells exhibited the double staining, 
demonstrating that RANK+ cells likely belong to subpopulations of activated macrophages or dendritic cells. 
 
Fig. 5. RANK expression in the colon by immunohistology. Representative examples of RANK immunostaining in 
CD and control tissues. (a,b). Immunoperoxydase staining. Detection of many RANK-positive cells in the 
mucosa of a CD biopsy specimen (magnification x400) (a); RANK immunostaining of mononuclear macrophage-
like cells (magnification x1000) (b); (c-e). Immunofluoresence detection of RANK-positive cells in normal colon 
tissue of a non CD (c) or CD (d) patient and in inflammatory colon tissue of a CD patient (e). (f,g). Double 
immunostaining demonstrating the presence of RANK (brown)/CD68 (red)-positive cells (f) and of RANK 
(brown)/S100 (red) positive cells (g) (magnification x1000). (h). No immunostaining in the mucosa of a CD 
biopsy specimen when the primary antibody is omitted (negative control). 
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DISCUSSION 
In this study, we have shown increased levels of OPG and sRANKL in the serum of patients with CD. We also 
demonstrated an increased production of OPG and sRANKL by the colonic mucosa in CD. Moreover, RANK 
was expressed in the human colonic wall, mainly in the mucosa and submucosa by mononuclear cells positive 
for CD68 and/or s100. The number of RANK-positive cells appeared to be increased in the colon of CD. 
RANKL is a critical factor for osteoclast differentiation and activation [14]. In the bone microenvironment, 
RANKL is produced by cells from the osteoblast lineage and its expression is induced after treatment with pro-
inflammatory cytokines. RANKL expression on T-cells is considered to play a major role in bone loss observed 
in rheumatoid arthritis, an inflammatory disease associated with joint destruction [11]. In CD, which is 
characterized by chronic systemic inflammation and decreased bone mass, expression of RANKL and production 
of sRANKL had never been studied until very recently [26]. In this recent study, serum levels of sRANKL were 
measured in a cohort of patients before and during glucocorticoid treatment. No significant change was observed 
although there was a significant decrease in BMD after 12 weeks [26]. Yet, sRANKL levels were not compared 
to levels in control subjects. Our data show that there is a significant increase in sRANKL serum levels in CD 
patients. Currently, available kits for sRANKL measurement only detect free sRANKL [27]. Therefore, the 
observed increase in sRANKL levels could be the result of a decrease in RANKL's decoy receptor OPG. This 
does not seem to be the case in our study as we found a concomitant increase in OPG levels. Functionally, the 
increase in OPG may counter-balance the effect of sRANKL on bone metabolism [15]. It is however, impossible 
to draw conclusions on the biological consequences of both OPG and sRANKL increase since their effect has to 
be considered in the bone, where the local concentration may be affected differently. 
Understanding the source of sRANKL and OPG protein levels in the serum is crucial. As already established, 
these mediators are synthesized by bone stromal cells and osteoblasts [14,15]. They may also be produced by 
activated DC and lymphocytes, mainly T lymphocytes for RANKL and B lymphocytes for OPG [11,13,14,16-
19]. As a dramatic increase in activated T and  B lymphocytes is present in the colonic mucosa and submucosa in 
CD [1], we looked at the production of OPG and sRANKL in the colon. After confirming the presence of both 
RANKL and OPG transcripts in the human colon, we observed a significant increase in both OPG and sRANKL 
levels in the culture media of colonic biopsies obtained from CD as compared to controls. OPG levels in the 
culture supernatant of colonic biopsies were significantly correlated to pro-inflammatory cytokines, suggesting 
that OPG is up-regulated in the colon as a result of chronic inflammation. In accordance with this observation, 
OPG is up-regulated in DC and primary B cells by activation through CD40 [16]. In osteoblasts, OPG synthesis 
is also enhanced by several cytokines including TNF-α [28]. Both CD40 expression and TNF-α production are 
increased in CD, potentially contributing to the observed increase in OPG protein levels [1,29]. 
While sRANKL was significantly increased in the culture supernatant of CD colonic biopsies as compared to 
controls, there was no further increase when comparing I and UN area of the colon in CD patients. Again, like in 
the serum, this may be due to a significant amount of sRANKL bound to OPG in the supernatant and therefore 
undetectable using our ELISA. Alternatively, RANKL may be differentiy affected by inflammation. However, 
this hypothesis is unlikely as pro-inflammatory cytokines are known to induce both RANKL and OPG 
expression [14]. RANKL mRNA is constitutively expressed in memory, but not naïve T-cells [13,19] and 
RANKL-expression in T cells is induced by antigen-receptor engagement [11,30]. The increase in sRANKL 
production described here in the colonic mucosa of CD may correspond to an increased proportion of memory 
activated T cells. 
Hence, we have shown that the colon may be an important source of RANKL and OPG in CD and we suggest 
that these locally produced mediators may spill out into the blood and possibly reach the bones where they can 
influence bone remodeling. Beyond this, the production of OPG and sRANKL in the colonic mucosa is 
intriguing since these mediators play a prominent role in lymphocytes and DC activation and differentiation and 
could therefore act locally by influencing the mucosal immune regulation. Nevertheless, the implication of 
sRANKL or RANKL in the regulation of the immune response in the bowel wall would require the local 
presence of its receptor RANK. Low levels of RANK mRNA have been described in the murine colon [14,15] 
but significant levels of the protein have been identified on mature DC [31]. We confirmed the presence of 
RANK transcripts in the normal human colon and RANK protein expression in the colon by immunostaining. 
RANK-expressing cells were mainly localized in the colon mucosa and had morphological features of large 
mononuclear cells suggestive of the monocyte-macrophage and/or dendritic cell lineages. Immunofluorescence 
data clearly showed increased densities of RANK+ cells in CD patients in uninvolved colon tissues with a further 
increase in involved areas. Double immunostaining experiments demonstrated that RANK+ cells likely belong to 
subpopulations of activated macrophages or dendritic cells. However the precise characterization of these 
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RANK+ cells will require further experiments using other more specific markers on frozen biopsy specimens and 
other techniques including confocal microscopy. 
Beyond its potential implication in bone remodeling, overex-pression of RANK, RANKL and OPG in colonic 
mucosa in CD may be relevant to CD pathophysiology. CD is characterized by an increased amount and 
activation of mononuclear cells in the bowel wall [1]. Particularly, T cells are abnormally resistant to apoptosis 
[32,33] and are thought to be sensitized against luminal material [1]. DCs play an important role in this abnormal 
T cells activation in CD although only few data are currently available on the specific phenotype and the 
activation of intestinal DCs in CD [34,35]. The intensity of an immune response is amplified by direct cell-cell 
contact between antigen-presenting cells and T-cells, through costimulatory molecules. For instance, CD40-
CD40L costimulatory proteins are most likely involved in CD as T-cells and DCs overexpress CD40L and 
CD40, respectively [28]. Interestingly, RANK is induced on DCs by CD40L stimulation [13]. While CD40-
CD40L interaction is mainly involved in early T/B cells priming and activation, RANK-RANKL binding may 
rather control later stage of activation and have a role in memory T cells responses [17]. As other TNFR family 
members, RANK can activate NF-κB in response to RANKL-expressing T lymphocytes [13]. Our data suggest 
that RANK-RANKL interaction on DCs and lymphocytes could contribute to the increased imuno-inflammatory 
reaction characterizing CD. This is in agreement with recent data on the mechanisms of colitis in IL2-deficient 
mice. In these mice, both colitis and osteopenia were caused by increased production of RANKL which, by 
acting via its receptor RANK, increases bone turnover but also promotes intestinal DC survival in vivo [36]. 
Locally, OPG may serve as a negative retro-control mediator on the differentiation, activation and increased 
survival of T cells and DCs in response to RANK-RANKL interaction leading to NF-κB activation. This is again 
in agreement with recent data on IL2-deficient mice. In this model, the treatment with exogenous recombinant 
OPG reversed skeletal abnormalities and reduced colitis by decreasing colonic DC number [36]. 
Another potentially relevant implication of OPG is its binding to tumour necrosis factor-α-related apoptosis-
inducing ligand (TRAIL), another member of the TNF superfamily [37]. TRAIL induces apoptosis of 
transformed and non transformed cells and high doses of OPG inhibit this process [37,38]. Excess of OPG could 
therefore leads to a lack of apoptosis in CD as observed in other systems [38]. However the affinity of OPG to 
TRAIL is lower than for RANKL and the in vivo relevance of TRAIL-OPG interaction has still to be established. 
In conclusion, our data show for the first time increased expression of RANK, RANKL and OPG in the colon of 
CD patients. These mediators and receptors may not only have a prominent role in bone loss associated to CD 
but also could have a considerable importance in the abnormal immune activation characterizing CD. Further 
functional studies will be necessary to clarify their respective role in CD. The study of other acute and chronic 
inflammatory disorders of the colon, including ulcerative colitis, will also be important to assess the specificity 
of the modifications described in this study. 
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